11 citations
,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
72 citations
,
April 2008 in “The Journal of urology/The journal of urology” Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.
9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
219 citations
,
October 2009 in “Steroids” 5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
May 2025 in “Reactions Weekly”
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
November 2013 in “Hair transplant forum international” Some generic finasteride may be counterfeit, leading to less effectiveness and increased hair loss.
23 citations
,
January 2012 in “International Food Research Journal” Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.
2 citations
,
March 2021 in “Reproduction” Finasteride may affect male fertility by interfering with specific sperm signaling.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
February 2026 in “European Urology”
3 citations
,
March 2020 in “The Journal of Urology” Older patients sticking to their prostate medication saw lasting health benefits.
29 citations
,
July 2012 in “The Journal of Sexual Medicine” Rats had lasting erectile problems after stopping a certain medication.
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
33 citations
,
January 2009 in “Journal of Cutaneous and Aesthetic Surgery” Finasteride reduces prostate cancer risk but may affect ejaculatory volume and requires careful consideration for young men.
1 citations
,
August 2015 in “Current Sexual Health Reports” 5α-reductase inhibitors can cause serious and possibly lasting sexual and psychological side effects.
December 2025 in “The AAPS Journal” Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.
4 citations
,
October 2020 in “Toxicology Mechanisms and Methods” Hesperidin protects rat testicles from finasteride damage and improves sperm health.
June 2018 in “Journal of Clinical Periodontology” Finasteride may cause gum problems, but stopping the drug can improve these issues.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
January 2004 in “Europe PMC (PubMed Central)” Finasteride sustained-release tablets are stable.
3 citations
,
October 2010 in “Wiley-VCH Verlag GmbH & Co. KGaA eBooks” Finasteride safely treats enlarged prostate and male-pattern baldness.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
April 2016 in “Journal of The American Academy of Dermatology” Dutasteride works better than finasteride for hair growth with similar side effects.
April 2025 in “The Journal of Urology” Long-term finasteride use may lower prostate cancer risk but increase the need for erectile dysfunction medication.
Finasteride tablets and capsules work the same in the body.
July 2024 in “Journal of Controlled Release” Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
8 citations
,
August 2021 in “Fertility and Sterility” Treatments for enlarged prostate can cause problems with ejaculation, and less invasive options might preserve sexual function better.